Regulatory T Cells in Cancer

Advances in Cancer Research

Volumn 107, Issue , 2010, Pages 57-117

  Mougiakakos, Dimitrios ^a   Choudhury, Aniruddha ^a   Lladser, Alvaro ^a   Kiessling, Rolf ^a   Johansson, C Christian ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASM; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION;

CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOMODULATION; NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 77951626075     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/S0065-230X(10)07003-X     Document Type: Chapter

References (348)

1. Ahmadzadeh, M., Rosenberg, S.A., IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107 (2006), 2409–2414.
2. Ai, W.Z., Hou, J.Z., Zeiser, R., Czerwinski, D., Negrin, R.S., Levy, R., Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int. J. Cancer 124 (2009), 239–244.
3. Akasaki, Y., Liu, G., Chung, N.H., Ehtesham, M., Black, K.L., Yu, J.S., Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173 (2004), 4352–4359.
4. Allan, S.E., Passerini, L., Bacchetta, R., Crellin, N., Dai, M., Orban, P.C., Ziegler, S.F., Roncarolo, M.G., Levings, M.K., The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J. Clin. Invest. 115 (2005), 3276–3284.
5. Alvaro, T., Lejeune, M., Salvado, M.T., Bosch, R., Garcia, J.F., Jaen, J., Banham, A.H., Roncador, G., Montalban, C., Piris, M.A., Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11 (2005), 1467–1473.
6. Andersen, M.H., Sorensen, R.B., Brimnes, M.K., Svane, I.M., Becker, J.C., thor Straten, P., Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J. Clin. Invest. 119 (2009), 2245–2256.
7. Angelini, G., Gardella, S., Ardy, M., Ciriolo, M.R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R., Rubartelli, A., Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl. Acad. Sci. USA 99 (2002), 1491–1496.
8. Annacker, O., Pimenta-Araujo, R., Burlen-Defranoux, O., Barbosa, T.C., Cumano, A., Bandeira, A., CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 166 (2001), 3008–3018.
9. Annacker, O., Asseman, C., Read, S., Powrie, F., Interleukin-10 in the regulation of T cell-induced colitis. J. Autoimmun. 20 (2003), 277–279.
10. Ansell, S.M., Hurvitz, S.A., Koenig, P.A., LaPlant, B.R., Kabat, B.F., Fernando, D., Habermann, T.M., Inwards, D.J., Verma, M., Yamada, R., Erlichman, C., Lowy, I., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15 (2009), 6446–6453.
11. Apostolou, I., von Boehmer, H., In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199 (2004), 1401–1408.
12. Apostolou, I., Sarukhan, A., Klein, L., von Boehmer, H., Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3 (2002), 756–763.
13. Attia, P., Maker, A.V., Haworth, L.R., Rogers-Freezer, L., Rosenberg, S.A., Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28 (2005), 582–592.
14. Azuma, T., Takahashi, T., Kunisato, A., Kitamura, T., Hirai, H., Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 63 (2003), 4516–4520.
15. Baban, B., Chandler, P.R., Sharma, M.D., Pihkala, J., Koni, P.A., Munn, D.H., Mellor, A.L., IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183 (2009), 2475–2483.
16. Bacchetta, R., Gregori, S., Roncarolo, M.G., CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun. Rev. 4 (2005), 491–496.
17. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W.H., Brasnu, D.F., Tartour, E., Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12 (2006), 465–472.
18. Baecher-Allan, C., Anderson, D.E., Regulatory cells and human cancer. Semin. Cancer Biol. 16 (2006), 98–105.
19. Baecher-Allan, C., Brown, J.A., Freeman, G.J., Hafler, D.A., CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167 (2001), 1245–1253.
20. Baecher-Allan, C., Viglietta, V., Hafler, D.A., Human CD4+CD25+ regulatory T cells. Semin. Immunol. 16 (2004), 89–98.
21. Banerjee, D.K., Dhodapkar, M.V., Matayeva, E., Steinman, R.M., Dhodapkar, K.M., Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108 (2006), 2655–2661.
22. Bardel, E., Larousserie, F., Charlot-Rabiega, P., Coulomb-L'Hermine, A., Devergne, O., Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 181 (2008), 6898–6905.
23. Baron, U., Floess, S., Wieczorek, G., Baumann, K., Grutzkau, A., Dong, J., Thiel, A., Boeld, T.J., Hoffmann, P., Edinger, M., Turbachova, I., Hamann, A., et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur. J. Immunol. 37 (2007), 2378–2389.
24. Bates, G.J., Fox, S.B., Han, C., Leek, R.D., Garcia, J.F., Harris, A.L., Banham, A.H., Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24 (2006), 5373–5380.
25. Battaglia, M., Roncarolo, M.G., Induction of transplantation tolerance via regulatory T cells. Inflamm. Allergy Drug Targets 5 (2006), 157–165.
26. Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T., Roncarolo, M.G., Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177 (2006), 8338–8347.
27. Bayer, A.L., Yu, A., Adeegbe, D., Malek, T.R., Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J. Exp. Med. 201 (2005), 769–777.
28. Belkaid, Y., Oldenhove, G., Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 29 (2008), 362–371.
29. Bennett, C.L., Christie, J., Ramsdell, F., Brunkow, M.E., Ferguson, P.J., Whitesell, L., Kelly, T.E., Saulsbury, F.T., Chance, P.F., Ochs, H.D., The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27 (2001), 20–21.
30. Bensinger, S.J., Bandeira, A., Jordan, M.S., Caton, A.J., Laufer, T.M., Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J. Exp. Med. 194 (2001), 427–438.
31. Berendt, M.J., North, R.J., T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151 (1980), 69–80.
32. Bergmann, C., Strauss, L., Zeidler, R., Lang, S., Whiteside, T.L., Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 67 (2007), 8865–8873.
33. Bettelli, E., Dastrange, M., Oukka, M., Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl. Acad. Sci. USA 102 (2005), 5138–5143.
34. Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P.A., Thomas, R.K., von Bergwelt-Baildon, M., Debey, S., Hallek, M., Schultze, J.L., Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005), 2018–2025.
35. Bonertz, A., Weitz, J., Pietsch, D.H., Rahbari, N.N., Schlude, C., Ge, Y., Juenger, S., Vlodavsky, I., Khazaie, K., Jaeger, D., Reissfelder, C., Antolovic, D., et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119 (2009), 3311–3321.
36. Bopp, T., Becker, C., Klein, M., Klein-Hessling, S., Palmetshofer, A., Serfling, E., Heib, V., Becker, M., Kubach, J., Schmitt, S., Stoll, S., Schild, H., et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204 (2007), 1303–1310.
37. Brahmer, J.R., Topalian, S.L., Powderly, J., Wollner, I., Picus, J., Drake, C.G., Stankevich, E., Korman, A., Pardoll, A., Lowy, I., Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J. Clin. Oncol. ASCO Annual Meeting Proceedings 27, 2009, 3018.
38. Brinkrolf, P., Landmeier, S., Altvater, B., Chen, C., Pscherer, S., Rosemann, A., Ranft, A., Dirksen, U., Juergens, H., Rossig, C., A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int. J. Cancer 125 (2009), 879–886.
39. Brusko, T.M., Wasserfall, C.H., Agarwal, A., Kapturczak, M.H., Atkins, M.A., An integral role for heme oxygenase-1 and carbon monoxide in maintaining peripheral tolerance by CD4+CD25+ regulatory T cells. J. Immunol. 174 (2005), 5181–5186.
40. Burnet, M., Cancer; a biological approach. I. The processes of control. Br. Med. J. 1 (1957), 779–786.
41. Cao, X., Cai, S.F., Fehniger, T.A., Song, J., Collins, L.I., Piwnica-Worms, D.R., Ley, T.J., Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27 (2007), 635–646.
42. Caramalho, I., Lopes-Carvalho, T., Ostler, D., Zelenay, S., Haury, M., Demengeot, J., Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197 (2003), 403–411.
43. Carreras, J., Lopez-Guillermo, A., Fox, B.C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E., Campo, E., Banham, A.H., High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 (2006), 2957–2964.
44. Chakraborty, N.G., Chattopadhyay, S., Mehrotra, S., Chhabra, A., Mukherji, B., Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum. Immunol. 65 (2004), 794–802.
45. Chaput, N., Louafi, S., Bardier, A., Charlotte, F., Vaillant, J.C., Menegaux, F., Rosenzwajg, M., Lemoine, F., Klatzmann, D., Taieb, J., Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58 (2009), 520–529.
46. Chatila, T.A., Role of regulatory T cells in human diseases. J. Allergy Clin. Immunol. 116 (2005), 949–959 quiz 960.
47. Chatila, T.A., Blaeser, F., Ho, N., Lederman, H.M., Voulgaropoulos, C., Helms, C., Bowcock, A.M., JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106 (2000), R75–R81.
48. Chauveau, C., Remy, S., Royer, P.J., Hill, M., Tanguy-Royer, S., Hubert, F.X., Tesson, L., Brion, R., Beriou, G., Gregoire, M., Josien, R., Cuturi, M.C., et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 106 (2005), 1694–1702.
49. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., Weiner, H.L., Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265 (1994), 1237–1240.
50. Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., Wahl, S.M., Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (2003), 1875–1886.
51. Chen, M.L., Pittet, M.J., Gorelik, L., Flavell, R.A., Weissleder, R., von Boehmer, H., Khazaie, K., Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA 102 (2005), 419–424.
52. Chen, W., Liang, X., Peterson, A.J., Munn, D.H., Blazar, B.R., The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181 (2008), 5396–5404.
53. Chung, D.J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D.H., Young, J.W., Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114 (2009), 555–563.
54. Clayton, A., Mitchell, J.P., Court, J., Mason, M.D., Tabi, Z., Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 67 (2007), 7458–7466.
55. Cobbold, S.P., Castejon, R., Adams, E., Zelenika, D., Graca, L., Humm, S., Waldmann, H., Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J. Immunol. 172 (2004), 6003–6010.
56. Cohen, A.C., Nadeau, K.C., Tu, W., Hwa, V., Dionis, K., Bezrodnik, L., Teper, A., Gaillard, M., Heinrich, J., Krensky, A.M., Rosenfeld, R.G., Lewis, D.B., Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J. Immunol. 177 (2006), 2770–2774.
57. Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S., Vignali, D.A., The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007), 566–569.
58. Colotta, F., Allavena, P., Sica, A., Garlanda, C., Mantovani, A., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009), 1073–1081.
59. Coombes, J.L., Siddiqui, K.R., Arancibia-Carcamo, C.V., Hall, J., Sun, C.M., Belkaid, Y., Powrie, F., A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204 (2007), 1757–1764.
60. Cortesini, R., LeMaoult, J., Ciubotariu, R., Cortesini, N.S., CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol. Rev. 182 (2001), 201–206.
61. Cosmi, L., Liotta, F., Lazzeri, E., Francalanci, M., Angeli, R., Mazzinghi, B., Santarlasci, V., Manetti, R., Vanini, V., Romagnani, P., Maggi, E., Romagnani, S., et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 102 (2003), 4107–4114.
62. Cosmi, L., Liotta, F., Angeli, R., Mazzinghi, B., Santarlasci, V., Manetti, R., Lasagni, L., Vanini, V., Romagnani, P., Maggi, E., Annunziato, F., Romagnani, S., Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood 103 (2004), 3117–3121.
63. Cupedo, T., Nagasawa, M., Weijer, K., Blom, B., Spits, H., Development and activation of regulatory T cells in the human fetus. Eur. J. Immunol. 35 (2005), 383–390.
64. Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K.L., Daniel, B., Zimmermann, M.C., David, O., Burow, M., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9 (2003), 562–567.
65. Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., Zhu, Y., Wei, S., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
66. Curotto de Lafaille, M.A., Lafaille, J.J., Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 30 (2009), 626–635.
67. Curotto de Lafaille, M.A., Kutchukhidze, N., Shen, S., Ding, Y., Yee, H., Lafaille, J.J., Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity 29 (2008), 114–126.
68. Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V., Bonanno, G., Rutella, S., Durelli, I., Horenstein, A.L., Fiore, F., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 109 (2007), 2871–2877.
69. Dang, N.H., Hagemeister, F.B., Pro, B., McLaughlin, P., Romaguera, J.E., Jones, D., Samuels, B., Samaniego, F., Younes, A., Wang, M., Goy, A., Rodriguez, M.A., et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22 (2004), 4095–4102.
70. Dannull, J., Su, Z., Rizzieri, D., Yang, B.K., Coleman, D., Yancey, D., Zhang, A., Dahm, P., Chao, N., Gilboa, E., Vieweg, J., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115 (2005), 3623–3633.
71. Dejaco, C., Duftner, C., Grubeck-Loebenstein, B., Schirmer, M., Imbalance of regulatory T cells in human autoimmune diseases. Immunology 117 (2006), 289–300.
72. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., Bhardwaj, N., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193 (2001), 233–238.
73. Dranoff, G., CTLA-4 blockade: unveiling immune regulation. J. Clin. Oncol. 23 (2005), 662–664.
74. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M., Robinson, M.R., Raffeld, M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002), 850–854.
75. Dudley, M.E., Wunderlich, J.R., Yang, J.C., Sherry, R.M., Topalian, S.L., Restifo, N.P., Royal, R.E., Kammula, U., White, D.E., Mavroukakis, S.A., Rogers, L.J., Gracia, G.J., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23 (2005), 2346–2357.
76. Dudley, M.E., Yang, J.C., Sherry, R., Hughes, M.S., Royal, R., Kammula, U., Robbins, P.F., Huang, J., Citrin, D.E., Leitman, S.F., Wunderlich, J., Restifo, N.P., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26 (2008), 5233–5239.
77. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002), 991–998.
78. Dye, E.S., North, R.J., T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J. Exp. Med. 154 (1981), 1033–1042.
79. Egen, J.G., Kuhns, M.S., Allison, J.P., CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3 (2002), 611–618.
80. Elpek, K.G., Lacelle, C., Singh, N.P., Yolcu, E.S., Shirwan, H., CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178 (2007), 6840–6848.
81. Ercolini, A.M., Ladle, B.H., Manning, E.A., Pfannenstiel, L.W., Armstrong, T.D., Machiels, J.P., Bieler, J.G., Emens, L.A., Reilly, R.T., Jaffee, E.M., Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201 (2005), 1591–1602.
82. Erdman, S.E., Poutahidis, T., Tomczak, M., Rogers, A.B., Cormier, K., Plank, B., Horwitz, B.H., Fox, J.G., CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162 (2003), 691–702.
83. Erdman, S.E., Sohn, J.J., Rao, V.P., Nambiar, P.R., Ge, Z., Fox, J.G., Schauer, D.B., CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res. 65 (2005), 3998–4004.
84. Erdman, S.E., Rao, V.P., Olipitz, W., Taylor, C.L., Jackson, E.A., Levkovich, T., Lee, C.W., Horwitz, B.H., Fox, J.G., Ge, Z., Poutahidis, T., Unifying roles for regulatory T cells and inflammation in cancer. Int. J. Cancer 126 (2009), 1651–1665.
85. Ermann, J., Fathman, C.G., Costimulatory signals controlling regulatory T cells. Proc. Natl. Acad. Sci. USA 100 (2003), 15292–15293.
86. Fallarino, F., Grohmann, U., Hwang, K.W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M.L., Fioretti, M.C., Alegre, M.L., Puccetti, P., Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4 (2003), 1206–1212.
87. Fallarino, F., Grohmann, U., You, S., McGrath, B.C., Cavener, D.R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M.L., Volpi, C., Santamaria, P., Fioretti, M.C., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176 (2006), 6752–6761.
88. Fantini, M.C., Becker, C., Monteleone, G., Pallone, F., Galle, P.R., Neurath, M.F., Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172 (2004), 5149–5153.
89. Figgitt, D.P., Lamb, H.M., Goa, K.L., Denileukin diftitox. Am. J. Clin. Dermatol. 1 (2000), 67–72 discussion 73.
90. Filaci, G., Suciu-Foca, N., CD8+ T suppressor cells are back to the game: are they players in autoimmunity?. Autoimmun. Rev. 1 (2002), 279–283.
91. Filaci, G., Fenoglio, D., Fravega, M., Ansaldo, G., Borgonovo, G., Traverso, P., Villaggio, B., Ferrera, A., Kunkl, A., Rizzi, M., Ferrera, F., Balestra, P., et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J. Immunol. 179 (2007), 4323–4334.
92. Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., Rivoltini, L., Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25 (2007), 2546–2553.
93. Fontenot, J.D., Gavin, M.A., Rudensky, A.Y., Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003), 330–336.
94. Fontenot, J.D., Dooley, J.L., Farr, A.G., Rudensky, A.Y., Developmental regulation of Foxp3 expression during ontogeny. J. Exp. Med. 202 (2005), 901–906.
95. Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., Rudensky, A.Y., Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005), 329–341.
96. Foss, F., Demierre, M.F., DiVenuti, G., A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106 (2005), 454–457.
97. Foussat, A., Cottrez, F., Brun, V., Fournier, N., Breittmayer, J.P., Groux, H., A comparative study between T regulatory type 1 and CD4+CD25+ T cells in the control of inflammation. J. Immunol. 171 (2003), 5018–5026.
98. Francois, V., Ottaviani, S., Renkvist, N., Stockis, J., Schuler, G., Thielemans, K., Colau, D., Marchand, M., Boon, T., Lucas, S., van der Bruggen, P., The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 69 (2009), 4335–4345.
99. Frankel, A.E., Surendranathan, A., Black, J.H., White, A., Ganjoo, K., Cripe, L.D., Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 106 (2006), 2158–2164.
100. Fu, J., Xu, D., Liu, Z., Shi, M., Zhao, P., Fu, B., Zhang, Z., Yang, H., Zhang, H., Zhou, C., Yao, J., Jin, L., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132 (2007), 2328–2339.
101. Fujimoto, S., Greene, M., Sehon, A.H., Immunosuppressor T cells in tumor bearing host. Immunol. Commun. 4 (1975), 201–217.
102. Furtado, G.C., Curotto de Lafaille, M.A., Kutchukhidze, N., Lafaille, J.J., Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196 (2002), 851–857.
103. Gao, Q., Qiu, S.J., Fan, J., Zhou, J., Wang, X.Y., Xiao, Y.S., Xu, Y., Li, Y.W., Tang, Z.Y., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25 (2007), 2586–2593.
104. Gao, Y.W., Chen, Y.X., Wang, Z.M., Jin, J., Li, X.Y., Zhou le, D., Huo, Z., Zhou, J.H., Chen, W., Increased expression of cyclooxygenase-2 and increased infiltration of regulatory T cells in tumors of patients with hepatocellular carcinoma. Digestion 79 (2009), 169–176.
105. Garin, M.I., Chu, C.C., Golshayan, D., Cernuda-Morollon, E., Wait, R., Lechler, R.I., Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109 (2007), 2058–2065.
106. Gavin, M.A., Torgerson, T.R., Houston, E., DeRoos, P., Ho, W.Y., Stray-Pedersen, A., Ocheltree, E.L., Greenberg, P.D., Ochs, H.D., Rudensky, A.Y., Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. USA 103 (2006), 6659–6664.
107. Generali, D., Bates, G., Berruti, A., Brizzi, M.P., Campo, L., Bonardi, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., Dogliotti, L., Banham, A.H., et al. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin. Cancer Res. 15 (2009), 1046–1051.
108. Gershon, R.K., Kondo, K., Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18 (1970), 723–737.
109. Gershon, R.K., Kondo, K., Infectious immunological tolerance. Immunology 21 (1971), 903–914.
110. Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P.E., Novault, S., Escudier, B., Vivier, E., Lecesne, A., Robert, C., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202 (2005), 1075–1085.
111. Ghiringhelli, F., Puig, P.E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., Zitvogel, L., Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202 (2005), 919–929.
112. Ghiringhelli, F., Menard, C., Puig, P.E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., Chauffert, B., Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2007), 641–648.
113. Gjerdrum, L.M., Woetmann, A., Odum, N., Burton, C.M., Rossen, K., Skovgaard, G.L., Ryder, L.P., Ralfkiaer, E., FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21 (2007), 2512–2518.
114. Gnjatic, S., Altorki, N.K., Tang, D.N., Tu, S.M., Kundra, V., Ritter, G., Old, L.J., Logothetis, C.J., Sharma, P., NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 15 (2009), 2130–2139.
115. Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A.C., Durand, I., Olive, D., Perez, S., Pasqual, N., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69 (2009), 2000–2009.
116. Gondek, D.C., Lu, L.F., Quezada, S.A., Sakaguchi, S., Noelle, R.J., Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174 (2005), 1783–1786.
117. Gounaris, E., Blatner, N.R., Dennis, K., Magnusson, F., Gurish, M.F., Strom, T.B., Beckhove, P., Gounari, F., Khazaie, K., T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 69 (2009), 5490–5497.
118. Gray, C.P., Arosio, P., Hersey, P., Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin. Cancer Res. 9 (2003), 2551–2559.
119. Griffiths, R.W., Elkord, E., Gilham, D.E., Ramani, V., Clarke, N., Stern, P.L., Hawkins, R.E., Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol. Immunother. 56 (2007), 1743–1753.
120. Gringhuis, S.I., Leow, A., Papendrecht-Van Der Voort, E.A., Remans, P.H., Breedveld, F.C., Verweij, C.L., Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J. Immunol. 164 (2000), 2170–2179.
121. Grossman, W.J., Verbsky, J.W., Barchet, W., Colonna, M., Atkinson, J.P., Ley, T.J., Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004), 589–601.
122. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J.E., Roncarolo, M.G., A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997), 737–742.
123. Haas, J., Schopp, L., Storch-Hagenlocher, B., Fritzsching, B., Jacobi, C., Milkova, L., Fritz, B., Schwarz, A., Suri-Payer, E., Hensel, M., Wildemann, B., Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis. Blood 111 (2008), 761–766.
124. Haas, M., Dimmler, A., Hohenberger, W., Grabenbauer, G.G., Niedobitek, G., Distel, L.V., Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol., 9, 2009, 65.
125. Hamdi, W., Ogawara, H., Handa, H., Tsukamoto, N., Nojima, Y., Murakami, H., Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. Eur. J. Haematol. 82 (2009), 201–207.
126. Han, G.M., O'Neil-Andersen, N.J., Zurier, R.B., Lawrence, D.A., CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell. Immunol. 253 (2008), 92–101.
127. Hawrylowicz, C.M., O'Garra, A., Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 5 (2005), 271–283.
128. Hiraoka, N., Onozato, K., Kosuge, T., Hirohashi, S., Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12 (2006), 5423–5434.
129. Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., Macrae, S., Nelson, M., Canning, C., Lowy, I., Korman, A., Lautz, D., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 105 (2008), 3005–3010.
130. Hoechst, B., Ormandy, L.A., Ballmaier, M., Lehner, F., Kruger, C., Manns, M.P., Greten, T.F., Korangy, F., A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135 (2008), 234–243.
131. Hori, S., Nomura, T., Sakaguchi, S., Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003), 1057–1061.
132. Huang, C.T., Workman, C.J., Flies, D., Pan, X., Marson, A.L., Zhou, G., Hipkiss, E.L., Ravi, S., Kowalski, J., Levitsky, H.I., Powell, J.D., Pardoll, D.M., et al. Role of LAG-3 in regulatory T cells. Immunity 21 (2004), 503–513.
133. Huber, S., Schramm, C., Lehr, H.A., Mann, A., Schmitt, S., Becker, C., Protschka, M., Galle, P.R., Neurath, M.F., Blessing, M., Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J. Immunol. 173 (2004), 6526–6531.
134. Huber, S., Stahl, F.R., Schrader, J., Luth, S., Presser, K., Carambia, A., Flavell, R.A., Werner, S., Blessing, M., Herkel, J., Schramm, C., Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells. J. Immunol. 182 (2009), 4633–4640.
135. Huehn, J., Hamann, A., Homing to suppress: address codes for Treg migration. Trends Immunol. 26 (2005), 632–636.
136. Hus, I., Schmitt, M., Tabarkiewicz, J., Radej, S., Wojas, K., Bojarska-Junak, A., Schmitt, A., Giannopoulos, K., Dmoszynska, A., Rolinski, J., Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22 (2008), 1007–1017.
137. Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., Fujii, H., Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. 9 (2003), 4404–4408.
138. Ishida, T., Ishii, T., Inagaki, A., Yano, H., Komatsu, H., Iida, S., Inagaki, H., Ueda, R., Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66 (2006), 5716–5722.
139. Iwasaki, A., Medzhitov, R., Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004), 987–995.
140. Jaafar, F., Righi, E., Lindstrom, V., Linton, C., Nohadani, M., Van Noorden, S., Lloyd, T., Poznansky, J., Stamp, G., Dina, R., Coleman, D.V., Poznansky, M.C., Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am. J. Pathol. 175 (2009), 1525–1535.
141. Jak, M., Mous, R., Remmerswaal, E.B., Spijker, R., Jaspers, A., Yague, A., Eldering, E., Van Lier, R.A., Van Oers, M.H., Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk. Lymphoma 50 (2009), 788–801.
142. Javia, L.R., Rosenberg, S.A., CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26 (2003), 85–93.
143. Jensen, H.K., Donskov, F., Nordsmark, M., Marcussen, N., von der Maase, H., Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin. Cancer Res. 15 (2009), 1052–1058.
144. Jeron, A., Pfoertner, S., Bruder, D., Geffers, R., Hammerer, P., Hofmann, R., Buer, J., Schrader, A.J., Frequency and gene expression profile of regulatory T cells in renal cell carcinoma. Tumour Biol. 30 (2009), 160–170.
145. Jiang, H., Chess, L., Regulation of immune responses by T cells. N. Engl. J. Med. 354 (2006), 1166–1176.
146. Joosten, S.A., van Meijgaarden, K.E., Savage, N.D., de Boer, T., Triebel, F., van der Wal, A., de Heer, E., Klein, M.R., Geluk, A., Ottenhoff, T.H., Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc. Natl. Acad. Sci. USA 104 (2007), 8029–8034.
147. Jordan, M.S., Boesteanu, A., Reed, A.J., Petrone, A.L., Holenbeck, A.E., Lerman, M.A., Naji, A., Caton, A.J., Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2 (2001), 301–306.
148. Jordanova, E.S., Gorter, A., Ayachi, O., Prins, F., Durrant, L.G., Kenter, G.G., van der Burg, S.H., Fleuren, G.J., Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. Clin. Cancer Res. 14 (2008), 2028–2035.
149. Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J., Chen, W., Kutok, J.L., Rabinovich, G.A., Shipp, M.A., The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA 104 (2007), 13134–13139.
150. Kanamaru, F., Youngnak, P., Hashiguchi, M., Nishioka, T., Takahashi, T., Sakaguchi, S., Ishikawa, I., Azuma, M., Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J. Immunol. 172 (2004), 7306–7314.
151. Kawaida, H., Kono, K., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N., Omata, H., Ooi, A., Fujii, H., Distribution of CD4+CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J. Surg. Res. 124 (2005), 151–157.
152. Kemper, C., Chan, A.C., Green, J.M., Brett, K.A., Murphy, K.M., Atkinson, J.P., Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421 (2003), 388–392.
153. Kiniwa, Y., Miyahara, Y., Wang, H.Y., Peng, W., Peng, G., Wheeler, T.M., Thompson, T.C., Old, L.J., Wang, R.F., CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13 (2007), 6947–6958.
154. Klemke, C.D., Fritzsching, B., Franz, B., Kleinmann, E.V., Oberle, N., Poenitz, N., Sykora, J., Banham, A.H., Roncador, G., Kuhn, A., Goerdt, S., Krammer, P.H., et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 20 (2006), 1123–1129.
155. Knutson, K.L., Dang, Y., Lu, H., Lukas, J., Almand, B., Gad, E., Azeke, E., Disis, M.L., IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177 (2006), 84–91.
156. Ko, K., Yamazaki, S., Nakamura, K., Nishioka, T., Hirota, K., Yamaguchi, T., Shimizu, J., Nomura, T., Chiba, T., Sakaguchi, S., Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 202 (2005), 885–891.
157. Kobayashi, N., Hiraoka, N., Yamagami, W., Ojima, H., Kanai, Y., Kosuge, T., Nakajima, A., Hirohashi, S., FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin. Cancer Res. 13 (2007), 902–911.
158. Kohm, A.P., McMahon, J.S., Podojil, J.R., Begolka, W.S., DeGutes, M., Kasprowicz, D.J., Ziegler, S.F., Miller, S.D., Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 176 (2006), 3301–3305.
159. Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N., Omata, H., Fujii, H., CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55 (2006), 1064–1071.
160. Kordasti, S.Y., Ingram, W., Hayden, J., Darling, D., Barber, L., Afzali, B., Lombardi, G., Wlodarski, M.W., Maciejewski, J.P., Farzaneh, F., Mufti, G.J., CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 110 (2007), 847–850.
161. Korn, T., Mitsdoerffer, M., Croxford, A.L., Awasthi, A., Dardalhon, V.A., Galileos, G., Vollmar, P., Stritesky, G.L., Kaplan, M.H., Waisman, A., Kuchroo, V.K., Oukka, M., IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 105 (2008), 18460–18465.
162. Kretschmer, K., Apostolou, I., Hawiger, D., Khazaie, K., Nussenzweig, M.C., von Boehmer, H., Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6 (2005), 1219–1227.
163. Krupnick, A.S., Gelman, A.E., Barchet, W., Richardson, S., Kreisel, F.H., Turka, L.A., Colonna, M., Patterson, G.A., Kreisel, D., Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J. Immunol. 175 (2005), 6265–6270.
164. Kryczek, I., Lange, A., Mottram, P., Alvarez, X., Cheng, P., Hogan, M., Moons, L., Wei, S., Zou, L., Machelon, V., Emilie, D., Terrassa, M., et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65 (2005), 465–472.
165. Kryczek, I., Wei, S., Zhu, G., Myers, L., Mottram, P., Cheng, P., Chen, L., Coukos, G., Zou, W., Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67 (2007), 8900–8905.
166. Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., Vatan, L., Finlayson, E., Huang, E., Simeone, D., Redman, B., Welling, T.H., et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res. 69 (2009), 3995–4000.
167. Kumar, V., Homeostatic control of immunity by TCR peptide-specific Tregs. J. Clin. Invest. 114 (2004), 1222–1226.
168. Kusmartsev, S., Nefedova, Y., Yoder, D., Gabrilovich, D.I., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172 (2004), 989–999.
169. Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., Fumoleau, P., Ghiringhelli, F., Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin. Cancer Res. 14 (2008), 2413–2420.
170. Larkin, J. III, Rankin, A.L., Picca, C.C., Riley, M.P., Jenks, S.A., Sant, A.J., Caton, A.J., CD4+CD25+ regulatory T cell repertoire formation shaped by differential presentation of peptides from a self-antigen. J. Immunol. 180 (2008), 2149–2157.
171. Lee, N.R., Song, E.K., Jang, K.Y., Choi, H.N., Moon, W.S., Kwon, K., Lee, J.H., Yim, C.Y., Kwak, J.Y., Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk. Lymphoma 49 (2008), 247–256.
172. Lee, S.Y., Choi, H.K., Lee, K.J., Jung, J.Y., Hur, G.Y., Jung, K.H., Kim, J.H., Shin, C., Shim, J.J., In, K.H., Kang, K.H., Yoo, S.H., The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 32 (2009), 22–28.
173. Leffers, N., Gooden, M.J., de Jong, R.A., Hoogeboom, B.N., ten Hoor, K.A., Hollema, H., Boezen, H.M., van der Zee, A.G., Daemen, T., Nijman, H.W., Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58 (2009), 449–459.
174. Lehe, C., Ghebeh, H., Al-Sulaiman, A., Al Qudaihi, G., Al-Hussein, K., Almohareb, F., Chaudhri, N., Alsharif, F., Al-Zahrani, H., Tbakhi, A., Aljurf, M., Dermime, S., The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res. 68 (2008), 6350–6359.
175. Leong, P.P., Mohammad, R., Ibrahim, N., Ithnin, H., Abdullah, M., Davis, W.C., Seow, H.F., Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol. Lett. 102 (2006), 229–236.
176. Levings, M.K., Sangregorio, R., Roncarolo, M.G., Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193 (2001), 1295–1302.
177. Levings, M.K., Sangregorio, R., Sartirana, C., Moschin, A.L., Battaglia, M., Orban, P.C., Roncarolo, M.G., Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196 (2002), 1335–1346.
178. Levings, M.K., Gregori, S., Tresoldi, E., Cazzaniga, S., Bonini, C., Roncarolo, M.G., Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105 (2005), 1162–1169.
179. Li, B., Lalani, A.S., Harding, T.C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M.J., Simmons, A.D., Jooss, K., Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12 (2006), 6808–6816.
180. Li, X., Ye, F., Chen, H., Lu, W., Wan, X., Xie, X., Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer Lett. 253 (2007), 144–153.
181. Li, W., Lidebjer, C., Yuan, X.M., Szymanowski, A., Backteman, K., Ernerudh, J., Leanderson, P., Nilsson, L., Swahn, E., Jonasson, L., NK cell apoptosis in coronary artery disease: relation to oxidative stress. Atherosclerosis 199 (2008), 65–72.
182. Li, J.F., Chu, Y.W., Wang, G.M., Zhu, T.Y., Rong, R.M., Hou, J., Xu, M., The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int. 103 (2009), 399–405.
183. Liang, S., Alard, P., Zhao, Y., Parnell, S., Clark, S.L., Kosiewicz, M.M., Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201 (2005), 127–137.
184. Liang, B., Workman, C., Lee, J., Chew, C., Dale, B.M., Colonna, L., Flores, M., Li, N., Schweighoffer, E., Greenberg, S., Tybulewicz, V., Vignali, D., et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 180 (2008), 5916–5926.
185. Lim, H.W., Hillsamer, P., Banham, A.H., Kim, C.H., Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J. Immunol. 175 (2005), 4180–4183.
186. Ling, K.L., Pratap, S.E., Bates, G.J., Singh, B., Mortensen, N.J., George, B.D., Warren, B.F., Piris, J., Roncador, G., Fox, S.B., Banham, A.H., Cerundolo, V., Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun., 7, 2007, 7.
187. Liston, A., Lesage, S., Wilson, J., Peltonen, L., Goodnow, C.C., Aire regulates negative selection of organ-specific T cells. Nat. Immunol. 4 (2003), 350–354.
188. Liu, H., Komai-Koma, M., Xu, D., Liew, F.Y., Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 103 (2006), 7048–7053.
189. Liu, W., Putnam, A.L., Xu-Yu, Z., Szot, G.L., Lee, M.R., Zhu, S., Gottlieb, P.A., Kapranov, P., Gingeras, T.R., de St, Fazekas, Groth, B., Clayberger, C., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203 (2006), 1701–1711.
190. Liu, V.C., Wong, L.Y., Jang, T., Shah, A.H., Park, I., Yang, X., Zhang, Q., Lonning, S., Teicher, B.A., Lee, C., Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J. Immunol. 178 (2007), 2883–2892.
191. Liu, Y., Zhang, P., Li, J., Kulkarni, A.B., Perruche, S., Chen, W., A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat. Immunol. 9 (2008), 632–640.
192. Liyanage, U.K., Moore, T.T., Joo, H.G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J.A., Strasberg, S.M., Eberlein, T.J., Goedegebuure, P.S., Linehan, D.C., Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169 (2002), 2756–2761.
193. Lohr, J., Knoechel, B., Abbas, A.K., Regulatory T cells in the periphery. Immunol. Rev. 212 (2006), 149–162.
194. Lopes, J.E., Soper, D.M., Ziegler, S.F., Foxp3 is required throughout the life of a regulatory T cell. Sci. STKE 2007, 2007 pe36.
195. Lopez, M.N., Pereda, C., Segal, G., Munoz, L., Aguilera, R., Gonzalez, F.E., Escobar, A., Ginesta, A., Reyes, D., Gonzalez, R., Mendoza-Naranjo, A., Larrondo, M., et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J. Clin. Oncol. 27 (2009), 945–952.
196. Lundqvist, A., Palmborg, A., Pavlenko, M., Levitskaya, J., Pisa, P., Mature dendritic cells induce tumor-specific type 1 regulatory T cells. J. Immunother. 28 (2005), 229–235.
197. Lutsiak, M.E., Semnani, R.T., De Pascalis, R., Kashmiri, S.V., Schlom, J., Sabzevari, H., Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105 (2005), 2862–2868.
198. Mahic, M., Yaqub, S., Johansson, C.C., Tasken, K., Aandahl, E.M., FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J. Immunol. 177 (2006), 246–254.
199. Mahnke, K., Ring, S., Johnson, T.S., Schallenberg, S., Schonfeld, K., Storn, V., Bedke, T., Enk, A.H., Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur. J. Immunol. 37 (2007), 2117–2126.
200. Mahnke, K., Schonfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T., Johnson, T.S., Storn, V., Schallenberg, S., Enk, A.H., Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120 (2007), 2723–2733.
201. Maker, A.V., Attia, P., Rosenberg, S.A., Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTL A-4 blockade. J. Immunol. 175 (2005), 7746–7754.
202. Malek, T.R., Yu, A., Vincek, V., Scibelli, P., Kong, L., CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17 (2002), 167–178.
203. Malmberg, K.J., Arulampalam, V., Ichihara, F., Petersson, M., Seki, K., Andersson, T., Lenkei, R., Masucci, G., Pettersson, S., Kiessling, R., Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J. Immunol. 167 (2001), 2595–2601.
204. Mantel, P.Y., Ouaked, N., Ruckert, B., Karagiannidis, C., Welz, R., Blaser, K., Schmidt-Weber, C.B., Molecular mechanisms underlying FOXP3 induction in human T cells. J. Immunol. 176 (2006), 3593–3602.
205. Marshall, N.A., Christie, L.E., Munro, L.R., Culligan, D.J., Johnston, P.W., Barker, R.N., Vickers, M.A., Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 (2004), 1755–1762.
206. McHugh, R.S., Whitters, M.J., Piccirillo, C.A., Young, D.A., Shevach, E.M., Collins, M., Byrne, M.C., CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002), 311–323.
207. Mehrotra, S., Mougiakakos, D., Johansson, C.C., Voelkel-Johnson, C., Kiessling, R., Oxidative stress and lymphocyte persistence: implications in immunotherapy. Adv. Cancer Res. 102 (2009), 197–227.
208. Miller, J.F., Immunological function of the thymus. Lancet 2 (1961), 748–749.
209. Miller, A.M., Lundberg, K., Ozenci, V., Banham, A.H., Hellstrom, M., Egevad, L., Pisa, P., CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177 (2006), 7398–7405.
210. Mills, K.H., Regulatory T cells: friend or foe in immunity to infection?. Nat. Rev. Immunol. 4 (2004), 841–855.
211. Misra, N., Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M.D., Kaveri, S.V., Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 172 (2004), 4676–4680.
212. Mizukami, Y., Kono, K., Kawaguchi, Y., Akaike, H., Kamimura, K., Sugai, H., Fujii, H., CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int. J. Cancer 122 (2008), 2286–2293.
213. Mizukami, Y., Kono, K., Kawaguchi, Y., Akaike, H., Kamimura, K., Sugai, H., Fujii, H., Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br. J. Cancer 98 (2008), 148–153.
214. Modigliani, Y., Bandeira, A., Coutinho, A., A model for developmentally acquired thymus-dependent tolerance to central and peripheral antigens. Immunol. Rev. 149 (1996), 155–174.
215. Moller, G., Do suppressor T cells exist?. Scand. J. Immunol. 27 (1988), 247–250.
216. Molling, J.W., de Gruijl, T.D., Glim, J., Moreno, M., Rozendaal, L., Meijer, C.J., van den Eertwegh, A.J., Scheper, R.J., von Blomberg, M.E., Bontkes, H.J., CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int. J. Cancer 121 (2007), 1749–1755.
217. Morgan, D.A., Ruscetti, F.W., Gallo, R., Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193 (1976), 1007–1008.
218. Morse, M.A., Hobeika, A.C., Osada, T., Serra, D., Niedzwiecki, D., Lyerly, H.K., Clay, T.M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112 (2008), 610–618.
219. Mosier, D.E., A requirement for two cell types for antibody formation in vitro. Science 158 (1967), 1573–1575.
220. Motta, M., Rassenti, L., Shelvin, B.J., Lerner, S., Kipps, T.J., Keating, M.J., Wierda, W.G., Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19 (2005), 1788–1793.
221. Mougiakakos, D., Johansson, C.C., Kiessling, R., Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 113 (2009), 3542–3545.
222. Mougiakakos, D., Johansson, C.C., Trocme, E., All-Ericsson, C., Economou, M.A., Larsson, O., Seregard, S., Kiessling, Cancer Epub, PMID: 20209608, 2010.
223. Mucida, D., Kutchukhidze, N., Erazo, A., Russo, M., Lafaille, J.J., Curotto de Lafaille, M.A., Oral tolerance in the absence of naturally occurring Tregs. J. Clin. Invest. 115 (2005), 1923–1933.
224. Munn, D.H., Mellor, A.L., Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117 (2007), 1147–1154.
225. Munn, D.H., Sharma, M.D., Hou, D., Baban, B., Lee, J.R., Antonia, S.J., Messina, J.L., Chandler, P., Koni, P.A., Mellor, A.L., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114 (2004), 280–290.
226. Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., Strober, W., TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172 (2004), 834–842.
227. Nicholaou, T., Ebert, L.M., Davis, I.D., McArthur, G.A., Jackson, H., Dimopoulos, N., Tan, B., Maraskovsky, E., Miloradovic, L., Hopkins, W., Pan, L., Venhaus, R., et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin. Cancer Res. 15 (2009), 2166–2173.
228. Nishikawa, H., Jager, E., Ritter, G., Old, L.J., Gnjatic, S., CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 106 (2005), 1008–1011.
229. Nocentini, G., Riccardi, C., GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur. J. Immunol. 35 (2005), 1016–1022.
230. North, R.J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155 (1982), 1063–1074.
231. Olkhanud, P.B., Baatar, D., Bodogai, M., Hakim, F., Gress, R., Anderson, R.L., Deng, J., Xu, M., Briest, S., Biragyn, A., Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res. 69 (2009), 5996–6004.
232. Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19 (2001), 376–388.
233. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59 (1999), 3128–3133.
234. Ormandy, L.A., Hillemann, T., Wedemeyer, H., Manns, M.P., Greten, T.F., Korangy, F., Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65 (2005), 2457–2464.
235. Pandiyan, P., Zheng, L., Ishihara, S., Reed, J., Lenardo, M.J., CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8 (2007), 1353–1362.
236. Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., Allison, J.P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206 (2009), 1717–1725.
237. Peng, G., Guo, Z., Kiniwa, Y., Voo, K.S., Peng, W., Fu, T., Wang, D.Y., Li, Y., Wang, H.Y., Wang, R.F., Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 (2005), 1380–1384.
238. Penhale, W.J., Farmer, A., McKenna, R.P., Irvine, W.J., Spontaneous thyroiditis in thymectomized and irradiated Wistar rats. Clin. Exp. Immunol. 15 (1973), 225–236.
239. Penna, G., Vulcano, M., Roncari, A., Facchetti, F., Sozzani, S., Adorini, L., Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J. Immunol. 169 (2002), 6673–6676.
240. Perrone, G., Ruffini, P.A., Catalano, V., Spino, C., Santini, D., Muretto, P., Spoto, C., Zingaretti, C., Sisti, V., Alessandroni, P., Giordani, P., Cicetti, A., et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur. J. Cancer 44 (2008), 1875–1882.
241. Petersen, R.P., Campa, M.J., Sperlazza, J., Conlon, D., Joshi, M.B., Harpole, D.H. Jr., Patz, E.F. Jr., Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107 (2006), 2866–2872.
242. Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Restifo, N.P., Haworth, L.R., Seipp, C.A., Freezer, L.J., Morton, K.E., Mavroukakis, S.A., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100 (2003), 8372–8377.
243. Piccirillo, C.A., Shevach, E.M., Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J. Immunol. 167 (2001), 1137–1140.
244. Prabhala, R.H., Neri, P., Bae, J.E., Tassone, P., Shammas, M.A., Allam, C.K., Daley, J.F., Chauhan, D., Blanchard, E., Thatte, H.S., Anderson, K.C., Munshi, N.C., Dysfunctional T regulatory cells in multiple myeloma. Blood 107 (2006), 301–304.
245. Pulko, V., Liu, X., Krco, C.J., Harris, K.J., Frigola, X., Kwon, E.D., Dong, H., TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J. Immunol. 183 (2009), 3634–3641.
246. Qin, X.J., Shi, H.Z., Deng, J.M., Liang, Q.L., Jiang, J., Ye, Z.J., CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin. Cancer Res. 15 (2009), 2231–2237.
247. Rech, A.J., Vonderheide, R.H., Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. N. Y. Acad. Sci. 1174 (2009), 99–106.
248. Ren, X., Ye, F., Jiang, Z., Chu, Y., Xiong, S., Wang, Y., Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells. Cell Death Differ. 14 (2007), 2076–2084.
249. Rifa'i, M., Kawamoto, Y., Nakashima, I., Suzuki, H., Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J. Exp. Med. 200 (2004), 1123–1134.
250. Roncador, G., Brown, P.J., Maestre, L., Hue, S., Martinez-Torrecuadrada, J.L., Ling, K.L., Pratap, S., Toms, C., Fox, B.C., Cerundolo, V., Powrie, F., Banham, A.H., Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur. J. Immunol. 35 (2005), 1681–1691.
251. Roncarolo, M.G., Gregori, S., Is FOXP3 a bona fide marker for human regulatory T cells?. Eur. J. Immunol. 38 (2008), 925–927.
252. Roncarolo, M.G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., Levings, M.K., Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212 (2006), 28–50.
253. Sakaguchi, S., Policing the regulators. Nat. Immunol. 2 (2001), 283–284.
254. Sakaguchi, S., Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004), 531–562.
255. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., Toda, M., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995), 1151–1164.
256. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
257. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., Iacopetta, B., Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27 (2009), 186–192.
258. Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., Takabayashi, A., CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98 (2003), 1089–1099.
259. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A.A., Frosina, D., Gnjatic, S., Ambrosone, C., Kepner, J., Odunsi, T., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102 (2005), 18538–18543.
260. Schaefer, C., Kim, G.G., Albers, A., Hoermann, K., Myers, E.N., Whiteside, T.L., Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92 (2005), 913–920.
261. Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S.K., Doni, A., Rapisarda, A., Bernasconi, S., Saccani, S., Nebuloni, M., Vago, L., Mantovani, A., Melillo, G., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J. Exp. Med. 198 (2003), 1391–1402.
262. Schmielau, J., Finn, O.J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61 (2001), 4756–4760.
263. Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S.I., Nanan, R., Kelleher, A., Fazekas de St Groth, B., Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203 (2006), 1693–1700.
264. Seo, N., Hayakawa, S., Takigawa, M., Tokura, Y., Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 103 (2001), 449–457.
265. Setoguchi, R., Hori, S., Takahashi, T., Sakaguchi, S., Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201 (2005), 723–735.
266. Sharma, S., Yang, S.C., Zhu, L., Reckamp, K., Gardner, B., Baratelli, F., Huang, M., Batra, R.K., Dubinett, S.M., Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 65 (2005), 5211–5220.
267. Shevach, E.M., Fatal attraction: tumors beckon regulatory T cells. Nat. Med. 10 (2004), 900–901.
268. Shimizu, J., Yamazaki, S., Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999), 5211–5218.
269. Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., Sakaguchi, S., Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3 (2002), 135–142.
270. Simpson, E., Special regulatory T-cell review: Regulation of immune responses–examining the role of T cells. Immunology 123 (2008), 13–16.
271. Sojka, D.K., Bruniquel, D., Schwartz, R.H., Singh, N.J., IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J. Immunol. 172 (2004), 6136–6143.
272. Somasundaram, R., Jacob, L., Swoboda, R., Caputo, L., Song, H., Basak, S., Monos, D., Peritt, D., Marincola, F., Cai, D., Birebent, B., Bloome, E., et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 62 (2002), 5267–5272.
273. Stanzer, S., Dandachi, N., Balic, M., Resel, M., Samonigg, H., Bauernhofer, T., Resistance to apoptosis and expansion of regulatory T cells in relation to the detection of circulating tumor cells in patients with metastatic epithelial cancer. J. Clin. Immunol. 28 (2008), 107–114.
274. Stephens, G.L., McHugh, R.S., Whitters, M.J., Young, D.A., Luxenberg, D., Carreno, B.M., Collins, M., Shevach, E.M., Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173 (2004), 5008–5020.
275. Strauss, L., Bergmann, C., Szczepanski, M.J., Lang, S., Kirkwood, J.M., Whiteside, T.L., Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J. Immunol. 180 (2008), 2967–2980.
276. Suciu-Foca, N., Cortesini, R., Central role of ILT3 in the T suppressor cell cascade. Cell. Immunol. 248 (2007), 59–67.
277. Suciu-Foca, N., Manavalan, J.S., Scotto, L., Kim-Schulze, S., Galluzzo, S., Naiyer, A.J., Fan, J., Vlad, G., Cortesini, R., Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int. Immunopharmacol. 5 (2005), 7–11.
278. Sun, C.M., Hall, J.A., Blank, R.B., Bouladoux, N., Oukka, M., Mora, J.R., Belkaid, Y., Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204 (2007), 1775–1785.
279. Sutmuller, R.P., den Brok, M.H., Kramer, M., Bennink, E.J., Toonen, L.W., Kullberg, B.J., Joosten, L.A., Akira, S., Netea, M.G., Adema, G.J., Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116 (2006), 485–494.
280. Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N., Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R., Melief, C.J., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001), 823–832.
281. Suzuki, H., Kundig, T.M., Furlonger, C., Wakeham, A., Timms, E., Matsuyama, T., Schmits, R., Simard, J.J., Ohashi, P.S., Griesser, H., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268 (1995), 1472–1476.
282. Suzuki, H., Onishi, H., Wada, J., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., Katano, M., Vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3(high)CD4(+) regulatory T cells. Eur. J. Immunol. 40 (2009), 197–203.
283. Szatrowski, T.P., Nathan, C.F., Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51 (1991), 794–798.
284. Tai, X., Cowan, M., Feigenbaum, L., Singer, A., CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6 (2005), 152–162.
285. Taieb, J., Chaput, N., Schartz, N., Roux, S., Novault, S., Menard, C., Ghiringhelli, F., Terme, M., Carpentier, A.F., Darrasse-Jeze, G., Lemonnier, F., Zitvogel, L., Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176 (2006), 2722–2729.
286. Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., Sakaguchi, S., Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10 (1998), 1969–1980.
287. Tan, M.C., Goedegebuure, P.S., Belt, B.A., Flaherty, B., Sankpal, N., Gillanders, W.E., Eberlein, T.J., Hsieh, C.S., Linehan, D.C., Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 182 (2009), 1746–1755.
288. Tanaka, H., Tanaka, J., Kjaergaard, J., Shu, S., Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25 (2002), 207–217.
289. Tang, H.L., Cyster, J.G., Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells. Science 284 (1999), 819–822.
290. Tang, Q., Boden, E.K., Henriksen, K.J., Bour-Jordan, H., Bi, M., Bluestone, J.A., Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 34 (2004), 2996–3005.
291. Thornton, A.M., Shevach, E.M., CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188 (1998), 287–296.
292. Thornton, A.M., Piccirillo, C.A., Shevach, E.M., Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur. J. Immunol. 34 (2004), 366–376.
293. Tiemessen, M.M., Mitchell, T.J., Hendry, L., Whittaker, S.J., Taams, L.S., John, S., Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J. Invest. Dermatol. 126 (2006), 2217–2223.
294. Tiemessen, M.M., Jagger, A.L., Evans, H.G., van Herwijnen, M.J., John, S., Taams, L.S., CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. USA 104 (2007), 19446–19451.
295. Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez, J.D., Zwirner, N.W., Poirier, F., Riley, E.M., Baum, L.G., Rabinovich, G.A., Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8 (2007), 825–834.
296. Turner, M.S., Kane, L.P., Morel, P.A., Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J. Immunol. 183 (2009), 4895–4903.
297. Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S.A., Dirnhofer, S., Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93 (2008), 193–200.
298. Vaclavkova, P., Cao, Y., Wu, L.K., Michalek, J., Vitetta, E.S., A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro. Bone Marrow Transplant. 37 (2006), 559–567.
299. van der Burg, S.H., Piersma, S.J., de Jong, A., van der Hulst, J.M., Kwappenberg, K.M., van den Hende, M., Welters, M.J., Van Rood, J.J., Fleuren, G.J., Melief, C.J., Kenter, G.G., Offringa, R., Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl. Acad. Sci. USA 104 (2007), 12087–12092.
300. van der Vliet, H.J., Koon, H.B., Yue, S.C., Uzunparmak, B., Seery, V., Gavin, M.A., Rudensky, A.Y., Atkins, M.B., Balk, S.P., Exley, M.A., Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13 (2007), 2100–2108.
301. van Maren, W.W., Jacobs, J.F., de Vries, I.J., Nierkens, S., Adema, G.J., Toll-like receptor signalling on Tregs: to suppress or not to suppress?. Immunology 124 (2008), 445–452.
302. van Santen, H.M., Benoist, C., Mathis, D., Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells. J. Exp. Med. 200 (2004), 1221–1230.
303. Vence, L., Palucka, A.K., Fay, J.W., Ito, T., Liu, Y.J., Banchereau, J., Ueno, H., Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 104 (2007), 20884–20889.
304. Venet, F., Pachot, A., Debard, A.L., Bohe, J., Bienvenu, J., Lepape, A., Powell, W.S., Monneret, G., Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177 (2006), 6540–6547.
305. Vignali, D.A., Collison, L.W., Workman, C.J., How regulatory T cells work. Nat. Rev. Immunol. 8 (2008), 523–532.
306. Viguier, M., Lemaitre, F., Verola, O., Cho, M.S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., Ferradini, L., Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173 (2004), 1444–1453.
307. von Boehmer, H., Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6 (2005), 338–344.
308. Vukmanovic-Stejic, M., Zhang, Y., Cook, J.E., Fletcher, J.M., McQuaid, A., Masters, J.E., Rustin, M.H., Taams, L.S., Beverley, P.C., Macallan, D.C., Akbar, A.N., Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116 (2006), 2423–2433.
309. Wada, J., Suzuki, H., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., Katano, M., The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res. 29 (2009), 881–888.
310. Walker, L.S., CD4+ CD25+ Treg: divide and rule?. Immunology 111 (2004), 129–137.
311. Walker, M.R., Kasprowicz, D.J., Gersuk, V.H., Benard, A., Van Landeghen, M., Buckner, J.H., Ziegler, S.F., Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112 (2003), 1437–1443.
312. Wang, H.Y., Lee, D.A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E.M., Wang, R.F., Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20 (2004), 107–118.
313. Wang, H.Y., Peng, G., Guo, Z., Shevach, E.M., Wang, R.F., Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 174 (2005), 2661–2670.
314. Wang, X., Zheng, J., Liu, J., Yao, J., He, Y., Li, X., Yu, J., Yang, J., Liu, Z., Huang, S., Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur. J. Haematol. 75 (2005), 468–476.
315. Wang, L., Pino-Lagos, K., de Vries, V.C., Guleria, I., Sayegh, M.H., Noelle, R.J., Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc. Natl. Acad. Sci. USA 105 (2008), 9331–9336.
316. Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., Weber, J., PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 21 (2009), 1065–1077.
317. Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., Zou, W., Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65 (2005), 5020–5026.
318. Wei, S., Kryczek, I., Zou, W., Regulatory T-cell compartmentalization and trafficking. Blood 108 (2006), 426–431.
319. Wei, S., Kryczek, I., Edwards, R.P., Zou, L., Szeliga, W., Banerjee, M., Cost, M., Cheng, P., Chang, A., Redman, B., Herberman, R.B., Zou, W., Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res. 67 (2007), 7487–7494.
320. Welters, M.J., Kenter, G.G., Piersma, S.J., Vloon, A.P., Lowik, M.J., Berends-van der Meer, D.M., Drijfhout, J.W., Valentijn, A.R., Wafelman, A.R., Oostendorp, J., Fleuren, G.J., Offringa, R., et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14 (2008), 178–187.
321. Wieckowski, E.U., Visus, C., Szajnik, M., Szczepanski, M.J., Storkus, W.J., Whiteside, T.L., Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J. Immunol. 183 (2009), 3720–3730.
322. Wieczorek, G., Asemissen, A., Model, F., Turbachova, I., Floess, S., Liebenberg, V., Baron, U., Stauch, D., Kotsch, K., Pratschke, J., Hamann, A., Loddenkemper, C., et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res. 69 (2009), 599–608.
323. Wilcox, R.A., Feldman, A.L., Wada, D.A., Yang, Z.Z., Comfere, N.I., Dong, H., Kwon, E.D., Novak, A.J., Markovic, S.N., Pittelkow, M.R., Witzig, T.E., Ansell, S.M., B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114 (2009), 2149–2158.
324. Wolf, M., Schimpl, A., Hunig, T., Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur. J. Immunol. 31 (2001), 1637–1645.
325. Wolf, A.M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., Grubeck-Loebenstein, B., Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9 (2003), 606–612.
326. Wolf, D., Wolf, A.M., Rumpold, H., Fiegl, H., Zeimet, A.G., Muller-Holzner, E., Deibl, M., Gastl, G., Gunsilius, E., Marth, C., The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 (2005), 8326–8331.
327. Wolf, D., Rumpold, H., Koppelstatter, C., Gastl, G.A., Steurer, M., Mayer, G., Gunsilius, E., Tilg, H., Wolf, A.M., Telomere length of in vivo expanded CD4(+)CD25(+) regulatory T-cells is preserved in cancer patients. Cancer Immunol. Immunother. 55 (2006), 1198–1208.
328. Woo, E.Y., Chu, C.S., Goletz, T.J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S.C., Kaiser, L.R., June, C.H., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61 (2001), 4766–4772.
329. Woo, E.Y., Yeh, H., Chu, C.S., Schlienger, K., Carroll, R.G., Riley, J.L., Kaiser, L.R., June, C.H., Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168 (2002), 4272–4276.
330. Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A.D., Stroud, J.C., Bates, D.L., Guo, L., Han, A., Ziegler, S.F., Mathis, D., Benoist, C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126 (2006), 375–387.
331. Xystrakis, E., Cavailles, P., Dejean, A.S., Cautain, B., Colacios, C., Lagrange, D., van de Gaar, M.J., Bernard, I., Gonzalez-Dunia, D., Damoiseaux, J., Fournie, G.J., Saoudi, A., Functional and genetic analysis of two CD8 T cell subsets defined by the level of CD45RC expression in the rat. J. Immunol. 173 (2004), 3140–3147.
332. Xystrakis, E., Dejean, A.S., Bernard, I., Druet, P., Liblau, R., Gonzalez-Dunia, D., Saoudi, A., Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 104 (2004), 3294–3301.
333. Yamagiwa, S., Gray, J.D., Hashimoto, S., Horwitz, D.A., A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J. Immunol. 166 (2001), 7282–7289.
334. Yan, Z., Garg, S.K., Kipnis, J., Banerjee, R., Extracellular redox modulation by regulatory T cells. Nat. Chem. Biol. 5 (2009), 721–723.
335. Yang, Y., Huang, C.T., Huang, X., Pardoll, D.M., Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5 (2004), 508–515.
336. Yang, Z.Z., Novak, A.J., Stenson, M.J., Witzig, T.E., Ansell, S.M., Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107 (2006), 3639–3646.
337. Yang, Z.Z., Novak, A.J., Ziesmer, S.C., Witzig, T.E., Ansell, S.M., Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 66 (2006), 10145–10152.
338. Yang, Z.Z., Novak, A.J., Ziesmer, S.C., Witzig, T.E., Ansell, S.M., CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 110 (2007), 2537–2544.
339. Yaqub, S., Henjum, K., Mahic, M., Jahnsen, F.L., Aandahl, E.M., Bjornbeth, B.A., Tasken, K., Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol. Immunother. 57 (2008), 813–821.
340. Yates, J., Rovis, F., Mitchell, P., Afzali, B., Tsang, J.Y., Garin, M., Lechler, R.I., Lombardi, G., Garden, O.A., The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int. Immunol. 19 (2007), 785–799.
341. Zenclussen, A.C., Regulatory T cells in pregnancy. Springer Semin. Immunopathol. 28 (2006), 31–39.
342. Zhang, L., Bertucci, A.M., Ramsey-Goldman, R., Burt, R.K., Datta, S.K., Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J. Immunol. 183 (2009), 6346–6358.
343. Zhao, D.M., Thornton, A.M., DiPaolo, R.J., Shevach, E.M., Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107 (2006), 3925–3932.
344. Zhou, G., Drake, C.G., Levitsky, H.I., Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107 (2006), 628–636.
345. Zhou, X., Bailey-Bucktrout, S., Jeker, L.T., Bluestone, J.A., Plasticity of CD4(+) FoxP3(+) T cells. Curr. Opin. Immunol. 21 (2009), 281–285.
346. Ziegler, S.F., FOXP3: not just for regulatory T cells anymore. Eur. J. Immunol. 37 (2007), 21–23.
347. Zorn, E., Nelson, E.A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R.J., Frank, D.A., Ritz, J., IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108 (2006), 1571–1579.
348. Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., Pustilnik, T., Curiel, D.T., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7 (2001), 1339–1346.